PROFILE OF THE YOUNG HYPERTENSIVE PATIENTS ADMITTED TO A DEPARTMENT OF INTERNAL MEDICINE

2011 ◽  
Vol 29 ◽  
pp. e416
Author(s):  
M. Á. Barón Ramos ◽  
A. A. Perez Rivera ◽  
A. Ruz Zafra ◽  
M. I. Maiz Jiménez ◽  
C. Luque Amado ◽  
...  
2020 ◽  
pp. 686-694

INTRODUCTION. The factors predisposing to the occurrence of cardiovascular event are mainly age, visceral obesity and metabolic syndrome. To our knowledge, there are no studies assessing both the nutritional status and diet of hypertensive patients in Poland. AIM. Our aim is the assessment of the diet and nutritional status of patients with hypertension. MATERIAL AND METHODS. This study included 50 patients (K: 32, M: 18) with hypertension admitted to the Department of Internal Medicine at the Heliodor Święcicki Clinical Hospital in Poznan. Anthropometric measurements (waist and hip circumference), and body composition analysis were used to assess nutritional status. Additionally, we carried out the nutritional interview. RESULTS. We observed that among hypertensive patients, overweight occurred in 18% and obesity (definition based on BMI) in 48% of all patients. We found that visceral obesity (definition based on WHR) concerns 76% of patients. Moreover, we diagnosed a metabolic syndrome in 56% of patients. None of the patients treated the DASH diet, especially recommended for the treatment of hypertension. What’s more, as many as 50% of hypertensive patients used salt for meals twice a day. CONCLUSIONS. In patients with hypertension the frequent occurrence of obesity and metabolic syndrome may to a large extent result from the dietary support deviating from the rational diet. There is a need to educate patients with arterial hypertension in the field of non-pharmacological treatment methods, especially diet therapy


2017 ◽  
Vol 1 (3) ◽  
Author(s):  
Hanny Merliana

Abstrak Hipertensi merupakan tantangan besar di Indonesia, berdasarkan data Riskesdas 2013 prevalensi kejadian sebesar 25% ser­ta kondisi yang sering ditemukan pada pelayanan kesehatan primer. Disamping itu, pengontrolan hipertensi belum adekuat meskipun obat-obatan yang efektif banyak tersedia. Amlodipine adalah salah satu obat hipertensi yang paling sering direse­pkan di RS X Pekanbaru. Untuk itu,dipandang perlumelakukan analisis minimisasi biaya dari pengggunaan amlodipine generik dan bermerek sebagai bentuk kendali mutu dan kendali biaya.Penelitian ini merupakan studi retrospektif yangmenggunakan data pasien hipertensi ringan sampai sedang dan periode pengobatan selama 1 bulan dari bulan Januari sampai Desember ta­hun 2015. Analisa CMA berdasarkan perspektif provider (rumah sakit sebagai pemberi pelayanan).Hasil analisis data ditemu­kan bahwa penggunaan amlodipin generik lebih banyak dibandingkan penggunaan obat bermerk di Poli Jantung dan Penyakit Dalam RS. X.Rerata biaya pengobatan dengan amlodipin generik Rp 68.660,- per bulan sedangkan dengan amlodipin ber­merk sebesar Rp. 374.844.- atau sekitar 5,4 kali lebih tinggi dari amlodipin generik. Penggunaan amlodipin generik maupun bermerk menurukan tekanan darah secara bermakna, namun tidak terdapat perbedaan bermakna antas penurunan tekanan darah yang dicapai dengan pemberian amlodipin generik maupun amlodipin bermerk. Disimpulkan bahwa amlodipin generik merupakan pilihan yang efisien dalam menurunkan tekanan darah dan memiliki biaya yang lebih efisien dibandingkan dengan amlodipin bermerk.Abstract Hypertension in a big challenge in Indonesia, proven by its prevalence that reached 25% in 2013 and conditions that mostly found in primary health care. In addition, hypertension management is considered to be suboptimal despite the availability of effective drugs. Amlodipine is one of anti-hypertensive that is commonly prescribed by X Hospital, Pekan Baru. Therefore, it is important to do cost minimization analysis to compare both generic and branded Amlodipine as an implementation of cost and quality control. This ret­rospective study involved early and medium stage of hypertensive patients that have at least a month period of treatment from Jan­uary to December 2015 using provider’s perspectives of CMA (Cost Minimization Analysis). The result showed that generic form of Amlodipine is the most common anti-hypertensive drugs prescribed in Cardiology and Internal Medicine Clinic, X Hospital. It was suggested that average cost of generic form of Amlodipine was IDR 68.660 while branded one was IDR 374.844 or approximately 5.4 times higher. Both generic and branded Amlodipine significantly reduced blood pressure, but there was not any distinguish effect between them. It was concluded that generic form of Amlodipine was a less expensive and efficient choice in reducing blood pressure.


2014 ◽  
Vol 19 (5) ◽  
pp. 13-15
Author(s):  
Stephen L. Demeter

Abstract A long-standing criticism of the AMA Guides to the Evaluation of Permanent Impairment (AMA Guides) has been the inequity between the internal medicine ratings and the orthopedic ratings; in the comparison, internal medicine ratings appear inflated. A specific goal of the AMA Guides, Sixth Edition, was to diminish, where possible, those disparities. This led to the use of the International Classification of Functioning, Disability, and Health from the World Health Organization in the AMA Guides, Sixth Edition, including the addition of the burden of treatment compliance (BOTC). The BOTC originally was intended to allow rating internal medicine conditions using the types and numbers of medications as a surrogate measure of the severity of a condition when other, more traditional methods, did not exist or were insufficient. Internal medicine relies on step-wise escalation of treatment, and BOTC usefully provides an estimate of impairment based on the need to be compliant with treatment. Simplistically, the need to take more medications may indicate a greater impairment burden. BOTC is introduced in the first chapter of the AMA Guides, Sixth Edition, which clarifies that “BOTC refers to the impairment that results from adhering to a complex regimen of medications, testing, and/or procedures to achieve an objective, measurable, clinical improvement that would not occur, or potentially could be reversed, in the absence of compliance.


Sign in / Sign up

Export Citation Format

Share Document